Journey Medical Corp

Research Journey Medical Corp (DERM) on Bullrun: market cap USD 208.26M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 208.26M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 61.24M-USD 11.43M-USD 12.44M65.8%-0.47USD 24.09MUSD 25.28MUSD 31.85M
FY2024USD 55.13M-USD 14.67M-USD 24.13M62.1%-0.72USD 20.31MUSD 24.88MUSD 20.07M
FY2023USD 59.66M-USD 3.85MUSD 240.00K61.6%-0.21USD 27.44MUSD 14.62MUSD 20.35M
FY2022USD 71.00M-USD 29.63M-USD 33.53M56.7%-1.69USD 32.00MUSD 19.83MUSD 16.98M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 208.26Mn/an/an/a
20252025-12-31USD 209.29Mn/an/an/a
20242024-12-31USD 86.62Mn/an/an/a
20232023-12-29USD 106.61Mn/an/an/a
20222022-12-30USD 34.11Mn/an/an/a
20212021-12-31USD 93.16Mn/an/an/a

About Journey Medical Corp

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Journey Medical Corp's market cap?

Journey Medical Corp's market capitalization is USD 208.26M.

What does Journey Medical Corp do?

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.